GlassScriptPhysician profile
Benjamin M Gentry
NPI 1811246317
$4,363.48
in general payments reported to CMS, 2019-2025
24 companies · $718 in 2025
The $718 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $994 · 2022: $1,032 · 2023: $1,038 · 2024: $582 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,197 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,197.25 |
| Education | $140.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $461.66 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $454.33 | 2021-2025 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals LP | $442.44 | 2021-2025 | Farxiga, Lokelma |
| Amgen INC. | $403.72 | 2021-2025 | Tavneos, Krystexxa |
| Vifor Pharma, INC. | $307.00 | 2021-2024 | Veltassa |
| Aurinia Pharma U.S., INC. | $262.70 | 2022-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $245.13 | 2022-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $209.29 | 2021-2023 | Rayaldee |
| Fresenius USA Marketing, INC. | $197.60 | 2021-2024 | Velphoro, Korsuva |
| Glaxosmithkline, LLC. | $194.58 | 2021-2024 | Benlysta, Jesduvroq |
| Otsuka America Pharmaceutical, INC. | $166.59 | 2022-2025 | Jynarque |
| Travere Therapeutics, INC. | $151.43 | 2021-2025 | Filspari |
| Novo Nordisk INC | $113.56 | 2025 | Ozempic |
| Alexion Pharmaceuticals, INC. | $107.26 | 2021-2024 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.64 | 2023-2025 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $100.31 | 2022-2024 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $85.62 | 2022-2025 | Gattex |
| Ani Pharmaceuticals, INC. | $84.17 | 2022-2024 | Purified Cortrophin Gel |
| Akebia Therapeutics INC | $76.87 | 2022-2025 | Vafseo |
| Horizon Therapeutics Plc | $69.82 | 2021-2023 | Krystexxa |
| Lilly USA, LLC | $45.14 | 2024 | Jardiance, Mounjaro |
| Ardelyx, INC. | $37.82 | 2023-2024 | Ibsrela |
| Xeris Pharmaceuticals, INC. | $22.19 | 2025 | Keveyis |
| Novartis Pharmaceuticals Corporation | $20.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Gentry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.